286 related articles for article (PubMed ID: 37021977)
1. Metabolic reprogramming of the ovarian cancer microenvironment in the development of antiangiogenic resistance.
Yue H; Lu X
Acta Biochim Biophys Sin (Shanghai); 2023 Apr; 55(6):938-947. PubMed ID: 37021977
[TBL] [Abstract][Full Text] [Related]
2. Anti-angiogenic therapy in ovarian cancer: current situation & prospects.
Liu Y; Luo Y; Cai M; Shen P; Li J; Chen H; Bao W; Zhu Y
Indian J Med Res; 2021 May; 154(5):680-690. PubMed ID: 35532586
[TBL] [Abstract][Full Text] [Related]
3. New insights into antiangiogenic therapy resistance in cancer: Mechanisms and therapeutic aspects.
Huang M; Lin Y; Wang C; Deng L; Chen M; Assaraf YG; Chen ZS; Ye W; Zhang D
Drug Resist Updat; 2022 Sep; 64():100849. PubMed ID: 35842983
[TBL] [Abstract][Full Text] [Related]
4. Are antiangiogenics a good 'partner' for immunotherapy in ovarian cancer?
García-Martínez E; Redondo A; Piulats JM; Rodríguez A; Casado A
Angiogenesis; 2020 Nov; 23(4):543-557. PubMed ID: 32691290
[TBL] [Abstract][Full Text] [Related]
5. State of the art and up-and-coming angiogenesis inhibitors for ovarian cancer.
Singh N; Badrun D; Ghatage P
Expert Opin Pharmacother; 2020 Sep; 21(13):1579-1590. PubMed ID: 32552175
[TBL] [Abstract][Full Text] [Related]
6. A Quininib Analogue and Cysteinyl Leukotriene Receptor Antagonist Inhibits Vascular Endothelial Growth Factor (VEGF)-independent Angiogenesis and Exerts an Additive Antiangiogenic Response with Bevacizumab.
Butler CT; Reynolds AL; Tosetto M; Dillon ET; Guiry PJ; Cagney G; O'Sullivan J; Kennedy BN
J Biol Chem; 2017 Mar; 292(9):3552-3567. PubMed ID: 28035003
[TBL] [Abstract][Full Text] [Related]
7. Biological Pathways Involved in Tumor Angiogenesis and Bevacizumab Based Anti-Angiogenic Therapy with Special References to Ovarian Cancer.
Loizzi V; Del Vecchio V; Gargano G; De Liso M; Kardashi A; Naglieri E; Resta L; Cicinelli E; Cormio G
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28906427
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer.
Teoh D; Secord AA
Int J Gynecol Cancer; 2012 Mar; 22(3):348-59. PubMed ID: 22266932
[TBL] [Abstract][Full Text] [Related]
9. Anti-Angiogenesis Therapy in Ovarian Cancer: Which Patient is It Most Likely to Benefit?
Chelariu-Raicu A; Coleman RL; Sood AK
Oncology (Williston Park); 2019 Jul; 33(7):. PubMed ID: 31365748
[TBL] [Abstract][Full Text] [Related]
10. IKKβ Regulates VEGF Expression and Is a Potential Therapeutic Target for Ovarian Cancer as an Antiangiogenic Treatment.
Kinose Y; Sawada K; Makino H; Ogura T; Mizuno T; Suzuki N; Fujikawa T; Morii E; Nakamura K; Sawada I; Toda A; Hashimoto K; Isobe A; Mabuchi S; Ohta T; Itai A; Morishige K; Kurachi H; Kimura T
Mol Cancer Ther; 2015 Apr; 14(4):909-19. PubMed ID: 25637316
[TBL] [Abstract][Full Text] [Related]
11. A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment.
Kerbel RS
Cancer J; 2015; 21(4):274-83. PubMed ID: 26222079
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.
Al Wadi K; Ghatage P
Expert Opin Pharmacother; 2016; 17(6):853-60. PubMed ID: 26933765
[TBL] [Abstract][Full Text] [Related]
13. Antiangiogenic therapies in epithelial ovarian cancer.
Teoh DG; Secord AA
Cancer Control; 2011 Jan; 18(1):31-43. PubMed ID: 21273978
[TBL] [Abstract][Full Text] [Related]
14. An angiogenic tumor phenotype predicts poor prognosis in ovarian cancer.
Wieser V; Tsibulak I; Reimer DU; Zeimet AG; Fiegl H; Hackl H; Marth C
Gynecol Oncol; 2023 Mar; 170():290-299. PubMed ID: 36758419
[TBL] [Abstract][Full Text] [Related]
15. Targeting angiogenesis in ovarian cancer.
Schmitt J; Matei D
Cancer Treat Rev; 2012 Jun; 38(4):272-83. PubMed ID: 21764518
[TBL] [Abstract][Full Text] [Related]
16. Turning promise into progress for antiangiogenic agents in epithelial ovarian cancer.
van der Bilt AR; de Vries EG; de Jong S; Timmer-Bosscha H; van der Zee AG; Reyners AK
Crit Rev Oncol Hematol; 2012 Nov; 84(2):224-42. PubMed ID: 22525643
[TBL] [Abstract][Full Text] [Related]
17. FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal.
Haemmerle M; Bottsford-Miller J; Pradeep S; Taylor ML; Choi HJ; Hansen JM; Dalton HJ; Stone RL; Cho MS; Nick AM; Nagaraja AS; Gutschner T; Gharpure KM; Mangala LS; Rupaimoole R; Han HD; Zand B; Armaiz-Pena GN; Wu SY; Pecot CV; Burns AR; Lopez-Berestein G; Afshar-Kharghan V; Sood AK
J Clin Invest; 2016 May; 126(5):1885-96. PubMed ID: 27064283
[TBL] [Abstract][Full Text] [Related]
18. Escaping Antiangiogenic Therapy: Strategies Employed by Cancer Cells.
Pinto MP; Sotomayor P; Carrasco-Avino G; Corvalan AH; Owen GI
Int J Mol Sci; 2016 Sep; 17(9):. PubMed ID: 27608016
[TBL] [Abstract][Full Text] [Related]
19. CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer.
Devapatla B; Sharma A; Woo S
PLoS One; 2015; 10(9):e0139237. PubMed ID: 26414070
[TBL] [Abstract][Full Text] [Related]
20. Classical and non-classical proangiogenic factors as a target of antiangiogenic therapy in tumor microenvironment.
Marech I; Leporini C; Ammendola M; Porcelli M; Gadaleta CD; Russo E; De Sarro G; Ranieri G
Cancer Lett; 2016 Sep; 380(1):216-26. PubMed ID: 26238184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
